Methodological aspects of ex vivo-generated monocyte-derived microglia-like cells in children with autism

Cover Page

Cite item

Full Text

Abstract

Current research findings suggest that dysregulation between the nervous and immune systems is a primary factor contributing to both initiation and progression of autism spectrum disorders (ASD). Microglia consists of resident brain immune cells playing a pivotal role in neuroinflammation and synaptic plasticity impairment. However, understanding these mechanisms has been limited by the lack of relevant experimental models. One promising approach involves microglia-like cells derived from peripheral blood monocytes (MDMi), which can serve as an effective model for studying human microglial function and developing personalized therapeutic strategies for neuropsychiatric diseases. The aim of our study was to optimize a protocol for generating sufficient quantities of microglia-like cells from peripheral blood monocytes of children with autism suitable for functional testing. Peripheral blood samples were collected from 18 children diagnosed with autism (mean age: 8.2 years; range: 6-12 years; 12 boys, 6 girls). Mononuclear cells were isolated using Ficoll density gradient centrifugation. After a 24-hour incubation period, adherent fractions enriched in monocytes were obtained via plate adherence. The monocytes were then cultured for either 10 or 14 days in serum-free RPMI-1640 medium supplemented with antibiotics and various cytokine cocktails to induce differentiation into MDMi. Viability was assessed using supravital staining with DAPI, while phenotyping was performed by flow cytometry targeting specific microglial markers such as P2RY12 and TMEM119. Statistical analyses were performed using PAST software version 4.03. Our findings demonstrate that successful induction of microglia-like cells requires, at least, a ten-day culture period with > 3 × 105 cells per well in RPMI-1640 medium containing stable glutamine, antibiotics, and a cocktail of three cytokines: GM-CSF, 10 ng/mL; IL-34, 100 ng/mL; IL-3, 10 ng/mL. Under these conditions, approximately 6 × 104 viable cells are generated, with over 90% expressing the microglial marker P2RY12. This cell population provides a valuable tool for studying ASD pathogenesis and identifying personalized treatment approaches.

About the authors

Yuliya Yu. Filippova

Chelyabinsk State University

Author for correspondence.
Email: julse@rambler.ru
ORCID iD: 0000-0001-5041-6440

PhD, MD (Biology), Associate Professor, Professor, Department of Microbiology, Immunology and General Biology, Faculty of Biology

Russian Federation, 129 Bratiev Kashirinykh St, Chelyabinsk, 454001

Kseniya A. Rusakova

Chelyabinsk State University

Email: ksenya.antipina.97@mail.ru

Postgraduate Student, Department of Microbiology, Immunology and General biology, Faculty of Biology

Russian Federation, 129 Bratiev Kashirinykh St, Chelyabinsk, 454001

Alexandra L. Burmistrova

Chelyabinsk State University

Email: burmal@csu.ru
ORCID iD: 0000-0001-6462-9500

PhD, MD (Medicine), Professor, Head, Department of Microbiology, Immunology and General Biology, Faculty of Biology

Russian Federation, 129 Bratiev Kashirinykh St, Chelyabinsk, 454001

References

  1. Andoh M., Ikegaya Y., Koyama R. Microglia as possible therapeutic targets for autism spectrum disorders. Prog. Mol. Biol. Transl. Sci., 2019, Vol. 167, pp. 223-245.
  2. Davit C.J., Hundley R.J., Bacic J.D., Hanson E.M. A pilot study to improve venipuncture compliance in children and adolescents with autism spectrum disorders. J. Dev. Behav. Pediatr., 2011, Vol. 32, no 7, pp. 521-525.
  3. Gebicke-Haerter P.J., Appel K., Taylor G.D., Schobert A., Rich I.N., Northoff H., Berger M. Rat microglial interleukin-3. J. Neuroimmunol., 1994, Vol. 50, no. 2, pp. 203-214.
  4. Heider J., Vogel S., Volkmer H., Breitmeyer R. Human iPSC-derived glia as a tool for neuropsychiatric research and drug development. Int. J. Mol. Sci., 2021, Vol. 22, no. 19, 10254. doi: 10.3390/ijms221910254.
  5. Llaves-López A., Micoli E., Belmonte-Mateos C., Aguilar G., Alba C., Marsal A., Pulido-Salgado M., Rabaneda-Lombarte N., Solà C., Serratosa J., Vidal-Taboada J.M., Saura J. Human microglia-like cells differentiated from monocytes with GM-CSF and IL-34 show phagocytosis of α-synuclein aggregates and C/EBPβ-dependent proinflammatory activation. Mol. Neurobiol., 2025, Vol. 62, no 1, pp. 756-772.
  6. Ohgidani M., Kato T.A., Setoyama D., Sagata N., Hashimoto R., Shigenobu K., Yoshida T., Hayakawa K., Shimokawa N., Miura D., Utsumi H., Kanba S. Direct induction of ramified microglia-like cells from human monocytes: dynamic microglial dysfunction in Nasu-Hakola disease. Sci. Rep., 2014, Vol. 4, 4957. doi: 10.1038/srep04957.
  7. Quek H., Cuní-López C., Stewart R., Lim Y.C., Roberts T.L., White A.R. A robust approach to differentiate human monocyte-derived microglia from peripheral blood mononuclear cells. STAR Protoc., 2022, Vol. 3, no 4, 101747. doi: 10.1016/j.xpro.2022.101747.
  8. Sargeant T.J., Fourrier C. Human monocyte-derived microglia-like cell models: A review of the benefits, limitations and recommendations. Brain Behav. Immun., 2023, Vol. 107, pp. 98-109.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2025 Filippova Y.Y., Rusakova K.A., Burmistrova A.L.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).